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Antioestrogen treatment by tamoxifen is a well-established adjuvant therapy for oestrogen receptor-alpha (ERa) positive breast
cancer. Despite ERa expression some tumours do not respond to tamoxifen and we therefore delineated the potential link between
the cell cycle regulator and ERa co-factor, cyclin D1, and tamoxifen response in a material of 167 postmenopausal breast cancers
arranged in a tissue array. The patients had been randomised to 2 years of tamoxifen treatment or no treatment and the median
follow-up time was 18 years. Interestingly in the 55 strongly ERa positive samples with moderate or low cyclin D1 levels, patients
responded to tamoxifen treatment whereas the 46 patients with highly ERa positive and cyclin D1 overexpressing tumours did not
show any difference in survival between tamoxifen and no treatment. Survival in untreated patients with cyclin D1 high tumours was
slightly better than for patients with cyclin D1 low/moderate tumours. However, there was a clearly increased risk of death in the
cyclin D1 high group compared to an age-matched control population. Our results suggest that cyclin D1 overexpression predicts for
tamoxifen treatment resistance in breast cancer, which is line with recent experimental data using breast cancer cell lines and
overexpression systems.
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Breast cancer is a highly heterogeneous disease that ideally should
be subcategorised according to genetic defects potentially reflect-
ing prognostic and predictive information in order to assure
optimal and individualised treatment for patients (Sorlie et al,
2001). Adjuvant treatment with antioestrogens like tamoxifen is
one of the most important treatment strategies used for breast
cancer, saving many lives. The presence of oestrogen receptor-
alpha (ERa) in tumour cells is essential for tamoxifen response,
and together with the progesterone receptor it serves as a
predictive factor for tamoxifen response in clinical practice
(EBCTC, 1998). Despite ERa expression some tumours do not
respond or develop resistance to tamoxifen treatment, suggesting
that the presence of ERa is not the only factor influencing
tamoxifen response (Ali and Coombes, 2002). Even though the
rationale for treatment failure is not fully comprehended, co-
factors to the ERa such as cyclin D1 might be implicated in the
process, theoretically blocking tamoxifen response. Cyclin D1 is a
cell cycle regulating protein with potential dual roles and in
addition to activating cdk 4/6 and sequestering of cdk-inhibitors in
the G1/S transition (Zhou et al, 2001), the protein has cdk-
independent functions and can act as a co-factor for ERa
independent of ligand (Neuman et al, 1997; Zwijsen et al, 1997,
1998; McMahon et al, 1999; Lamb et al, 2000). It has further been
shown that cyclin D1 overexpression can affect tamoxifen response
in breast cancer cell lines (Hui et al, 2002), but contradictory
results have nevertheless been published regarding this potentially
important feature for cyclin D1 (Pacilio et al, 1998; Bindels et al,
2002). No randomised clinical studies detailing cyclin D1 in ERa
positive breast cancer with regards to tamoxifen response have
been reported. Cyclin D1 knockout mice show a marked defect in
breast epithelium development during pregnancy (Sicinski et al,
1995) and tissue-specific overexpression of cyclin D1 leads to
mammary hyperplasia and adenocarcinoma formation in mice
models (Wang et al, 1994), supporting the relevance for cyclin D1
in breast cancer development.
Besides a potential role for cyclin D1 in ERa response, cyclin
D1 has also been linked to prognostic information in breast
cancer. Cyclin D1 gene amplification in sporadic tumours
as well as cyclin D1 RNA expression in ERa positive breast
cancer has been correlated to poor prognosis (Kenny et al, 1999;
Bieche et al, 2002; Naidu et al, 2002). When studying protein levels,
cyclin D1 overexpression has in contrast been associated with
better outcome (Gillett et al, 1996; Hwang et al, 2003).
Furthermore, cyclin D1 overexpression has been closely linked to
ERa positivity (Michalides et al, 1996; van Diest et al, 1997). In
order to better clarify the role of cyclin D1 in breast cancer we
analysed a material of randomised postmenopausal breast cancer
patients with long follow-up. Interestingly, cyclin D1 overexpres-
sion was associated with tamoxifen resistance despite the presence
of ERa. Tumours overexpressing cyclin D1 were further associated
with a slightly improved survival, and in summary we show that
randomised treatment trials including an untreated control arm
are necessary in order to differ predictive and prognostic
information.
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Study design
Between 1980 and 1987, 248 patients with primary breast cancer
were enrolled in a clinical trial (EBCTC, 1998) in the Northern
Health Region of Sweden and randomised to adjuvant tamoxifen
treatment (40mg daily), n¼123, for 2 years vs control, n¼125.
The aim of the study was to compare the effect of tamoxifen vs no
treatment on overall survival. The inclusion criteria were
postmenopausal patients 455 years of age operated with modified
radical mastectomy with curative intent. Postoperative radio-
therapy was given to all patients with lymph node metastases.
Hormone receptor status was not evaluated at time of diagnosis.
The median age at diagnosis was 66.5 years (55–75 years), the
median tumour size was 25mm (40–76mm) and 159 node-
negative patients and 86 node-positive patients were encountered.
According to TNM-classification 65 patients with stage I disease,
175 patients with stage II and five patients with stage III disease,
were included in survival analyses. Three patients could not be
classified according to TNM.
The median follow-up time was 18 years (range 15–22 years) for
surviving patients. At 10-years of follow-up 72 patients (58%) were
alive in the control group and 76 (62%) in the tamoxifen group. In
the control group 53 (42%) patients had died and in the tamoxifen
group 47 (38%) patients had died. At the last follow-up 34% of the
patients in the control group were alive, whereas 66% had died. In
the tamoxifen group 34% were alive and 66% had died. All
clinicopathological data together with clinical outcome are
summarised according to treatment arm in Table 1.
Tissue array and immunohistochemistry
Representative parts of the tumours were assembled in a tissue
array using a manual tissue arrayer (Beecher Instruments Micro-
array Technology, Woodland, MD, USA). For immunohistochem-
istry, paraffin sections of 4mm were de-paraffinised using xylen
and rehydrated using descending concentrations of ethanol
according to standard protocol. Antigen retrieval was achieved
using 10mM citrate buffer at pH 6.0 and microwave treatment,
before incubations with antibodies to the ERa (M7047, 1:200,
Dako A/S, Glostrup, Denmark) and cyclin D1 (M7155, 1:100,
Dako). All stainings were performed in a Dako Techmate 500
(Dako). The specificity of the antibodies was confirmed by
comparing the immunohistochemistry stainings of cell lines with
Western blot reactivity (data not shown).
Analytical procedures
The randomised study included both ERa positive and ERa
negative breast cancers and we therefore initially delineated the
fraction of ERa positive tumour cells in four groups (0, o10, 10–
90 and 490%) for each patient. ERa was scored as positive if
410% and the subfraction of 490% was used for the analyses of a
homogenous group of potentially highly tamoxifen responsive
tumours. Cyclin D1 protein was monitored by two investigators
scoring the tissue array samples according to intensity and fraction
of the nuclear staining. Fraction was scored according to the same
criteria as ERa and intensity was subjectively divided into four
groups (negative, low, moderate, high), see Table 1. By using tissue
array, staining variations between samples were minimised and
positive samples could be used as supplements for internal
controls. Concordance between the investigators was high and in
the few cases of differing results, biopsies were re-evaluated and
discussed to reach consensus. Relevant tissue array biopsies for
ERa/cyclin D1 analyses were obtained for 167 tumours. In total, 56
biopsies contained insufficient tumour cells or did not sustain the
staining process. A total of 44 tumours were ERa negative (0–10%
positive fraction), 22 had 10–90% and 101 490% ERa positive
cells (Table 2). For the survival analysis both intensity and fraction
of cyclin D1 were used (Tables 2 and 3).
Statistical analysis
Kaplan–Meier’s plot and log rank test were used when illustrating
and calculating survival. All calculations were performed in SPSS
version 11.0. An age-matched survival estimate for a control
population in southern Sweden was obtained from the Cancer
Registry in Lund, Sweden.
Table 1 Patient and tumour characteristics according to treatment
Variable
Tamoxifen treated
patients (n¼123) Control (n¼125)
Age (years) median 66.2 (54.9–74.7) 66.8 (55.2–74.9)
Age (number)
4Median 66 years 60 65
oMedian 66 years 63 60
Tumour size
Median (mm) 25.0 (3–55) 24.5 (40–76)
Size not known 2 0
Node status
Node  80 79
Node+ 41 45
Not known 2 1
Stage
I3 0 3 5
II 90 85
III 1 4
Not known 2 1
ERa fraction
0–10% 19 29
10–90% 14 12
490% 53 55
Not known 37 (30%) 29 (23%)
PR fraction
0–10% 47 50
10–90% 20 22
490% 17 18
Not known 39 (32%) 35 (28%)
Cyclin D1 fraction
0–10% 21 21
10–90% 53 53
490% 9 15
Not known 40 (33%) 36 (29%)
Cyclin D1 intensity
Negative 0 1
Low 4 5
Moderate 50 49
High 29 34
Not known 40 (33%) 36 (29%)
10-year FU
Alive 76 72
Dead 47 53
Maximum FU
Alive 42 42
Dead 81 83
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Of the 248 patients included in the randomised treatment trial,
formalin-fixed material was available for 223 tumours and 106 of
these patients were randomised to tamoxifen treatment and 117 to
observation, as described in Figure 1. Of the 182 breast cancer
samples that were possible to evaluate for ERa in the array, 74%
were classified as positive, which is in agreement with other
reports including postmenopausal patients (Elwood and God-
olphin, 1980). In total, 59% of the tumours showed 490% ERa
positive cells, which is slightly higher than expected compared to
ELISA-based analyses (Thorpe et al, 1993). A summary of the 172
samples that were possible to evaluate for cyclin D1, including
intensity and fraction is presented in Table 1. The cyclin D1 and
ERa analyses combined are presented in Tables 2 and 3. The
fraction of cyclin D1 positive tumour cells and the cyclin D1
intensity determinations correlated significantly (Po0.0001,
r¼0.463) and were both used for the following survival analysis
regarding tamoxifen response.
In the total cohort consisting of both ERa positive and negative
tumours, tamoxifen treatment did not improve prognosis
(Figure 2A). Patients with tumours lacking or expressing low
ERa did, as expected, not show any significant difference in
survival with tamoxifen, whereas there was a slightly improved
survival for patients with tumours having 410% ERa positive
cells (P¼0.4055 after 10 years of follow-up and P¼0.6000 after
22 years). The 108 tumours with 490% ERa positive cells
showed nevertheless a more pronounced response to tamoxifen
treatment as illustrated in Figure 2B, supporting that there
was an increased effect of adjuvant tamoxifen treatment
in ERa high tumours compared to tumours with moderately
elevated ERa levels. In order to delineate the effect of cyclin
D1 expression in relation to tamoxifen response, overall survival
in patients with ERa positive tumours was stratified according
to the fraction and intensity of cyclin D1 expression and potential
differences between tamoxifen and no treatment were evaluated.
The fraction of cyclin D1 positive cells did not seem to influence
the effect of tamoxifen treatment and survival curves with an
apparent tamoxifen benefit were comparable in the cyclin D1
fraction subgroups (data not shown). Similar results were
obtained both for the entire ERa positive cohort and the subgroup
of 490% ERa positive tumours. In contrast, the cyclin D1
intensity analyses showed substantial differences in tamoxifen
response. A total of 45% of the 101 ERa high tumours had high
cyclin D1 intensity staining whereas 50% had moderate and 5%
were cyclin D1 low. By this definition, around half of the ERa
positive tumours overexpressed cyclin D1, which is in line with
earlier reports (Gillett et al, 1996; Michalides et al, 1996). When
analysing all ERa positive tumours separating moderate/low cyclin
D1 from high cyclin D1 tumours, a clear distinction in tamoxifen
response was observed. In the group with lower cyclin D1, there
was a difference in survival between tamoxifen and no treatment in
the entire ERa positive cohort (P¼0.0509 at 10 years and
P¼0.0927 at 22 years). When analysing the 101 tumours with
490% ERa positive cells this effect was even more distinct
(P¼0.0077 at 10 years, P¼0.0211 at 22 years), as illustrated in
Figure 2C. Surprisingly, the difference between tamoxifen and no
treatment was completely eliminated for tumours with high cyclin
D1 (Figure 2D). This suggests that overexpression of cyclin D1 was
Table 2 Cyclin D1 intensity and ERa fraction analysis
ERa fraction
Cyclin D1 intensity 0–10% 10–90% 490%
Negative 1 0 0
Low 3 1 5
Moderate 35 13 50
High 5 8 46
Total (n¼167) 44 22 101
Table 3 Cyclin D1 fraction and ERa fraction analysis
ERa fraction
Cyclin D1 fraction 0–10% 10–90% 490%
0–10% 28 5 7
10–90% 16 15 74
490% 0 2 20
Total (n¼167) 44 22 101
248 patients
25 patients
no available archive material
17 patients
tamoxifen treatment
8 patients
no adjuvant treatment
223 patient
tumours included in the tissue microarray
106 patients
tamoxifen treatment
117 patients
no adjuvant treatment
67 ER 
positive
19 ER 
negative
29 ER 
negative
20 no ER  results* 21 no ER  results*
67 ER 
positive
29 Cyclin D1
high
54 Cyclin D1
low/moderate
34 Cyclin D1
high
55 Cyclin D1
low/moderate
23 no Cyclin D1 results* 28 no Cyclin D1 results*
Figure 1 Illustration of the patient material, randomisation and distribution of the analyses results. ERa positivity is 410% positive cells and the cyclin D1
results are based on intensity determinations. *No evaluable tumour cells in the array or the tumour did not sustain the staining process.
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ylinked to tamoxifen treatment resistance despite high and
homogenous ERa content.
Regarding survival and cyclin D1, the untreated control
patients could be used to evaluate true prognostic information
without the interference of treatment differences. The fraction
of cyclin D1 positive cells was not associated with any prognostic
data whereas there was a difference in survival for cyclin D1
groups based on intensity determination, as illustrated in Figure 3.
For all untreated patients there was a mortality rate of 56 and
71% respectively for patients with cyclin D1 high contra cyclin
D1 moderate/low tumours (Figure 3A). In the group of 490%
ERa positive tumours, there was an even more noticeable
difference in survival for cyclin D1 high contra moderate/low
tumours with mortality rates of 48 and 85% respectively
(Figure 3B). This suggests that high levels of cyclin D1 were
associated with an overall better prognosis than moderate or
low cyclin D1 levels in untreated patients. Interestingly, the
opposite was observed when analysing patients treated with
tamoxifen only (Figure 3C) and especially when focusing on a
rather short follow-up time. The apparent contrasting results
for patients that received tamoxifen or not, clearly illustrates
the importance of an untreated control patient group for
prognostic studies and might further explain earlier divergent
results reported concerning cyclin D1 and prognosis. The reason
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Figure 2 Kaplan–Meier plots for overall survival indicating randomisation to 2 years of tamoxifen treatment contra no treatment. (A) Overview of the
entire cohort including both ERa positive and negative tumours. (B) The subgroup of 101 490% ERa positive breast cancer samples. (C, D) Overall survival
for patients having tumours with 490% ERa positivity in relation to cyclin D1 intensity (low/moderate or high expression). P-values are presented in a box
with values at 10 years of follow-up (22 years of follow-up in parenthesis).
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different results regarding prognostic as well as predictive
information is not clear. The fraction of cyclin D1 must be
affected by the amount of cells in different cell cycle phases
whereas the intensity potentially reflects the maximum protein
expression independent of total proliferation. Cyclin D1 nuclear
intensity has previously been linked to the degree of amplification
of the cyclin D1 gene (Michalides et al, 1996). It is well known that
high cyclin D1 protein content in tumours is not always caused by
gene amplification (Buckley et al, 1993) and this might also
influence the cyclin D1 fraction and intensity measurements in this
material of breast cancer samples.
Our results using randomised untreated or tamoxifen treated
patients with a long follow-up period indicate that cyclin D1
indeed affects tamoxifen response, which is in line with some of
the published data using cell lines. In contrast to this study, Han
et al (2003) did not observe any difference in tamoxifen response
in metastatic breast cancer when studying cyclin D1. This study
was nevertheless rather limited and the patients were not
randomised, which might explain the discrepancy. The most likely
mechanistic explanation for the effect of cyclin D1 on tamoxifen
response is either through a direct interaction between cyclin D1
and the ERa/SRC-1 complex or via its cell cycle regulatory
function, as also supported by cell line studies (Zwijsen et al,
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Figure 3 Overall survival in relation to cyclin D1 intensity (low/moderate and high) in (A) all untreated patients, (B) untreated patients with 490% ERa
positive cells and (C) tamoxifen treated patients with 490% ERa positive cells. P-values are presented in a box with values at 10 years of follow-up (22 years
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tamoxifen on the ERa despite theoretically causing an oestrogen-
independent low activation. An alternative model is that cyclin D1
could sequester cdk-inhibitors, thereby affecting the G1/S control
and tamoxifen response.
It thus seems that a large fraction of patients who receive
tamoxifen do not benefit from it and this could partially be
mediated through cyclin D1. Despite the rather favourable
prognosis for cyclin D1 high breast cancer patients, a substantial
fraction indeed die in advance as illustrated in Figure 4, showing
the overall survival for patients with cyclin D1 high tumours
compared to the expected survival in an aged-matched population.
The outcome for this large cohort of breast cancer patients could
nevertheless theoretically be improved by specifically targeting
cyclin D1 in conjunction with tamoxifen, representing a new
treatment strategy for tamoxifen resistance in ERa positive cyclin
D1 overexpressing breast cancer.
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